Imagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough Awards

Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry

TEL AVIV, Israel - November 3, 2022 - (

Imagene, an emerging leader in the field of AI-based precision oncology, today announced it has been selected as "Oncology Innovation of the Year" in the second annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry's most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year's program attracted more than 1,350 nominations from over 12 different countries throughout the world. Imagene's AI-based Biomarker Detection was chosen as a breakthrough innovation in the field of Medical Technology.

Imagene is a pioneer startup in the Digital Genomics space. Using computer vision algorithms, the company can detect in real-time cancerous genomic alterations directly from the biopsy slide (H&E) scanned image. The idea behind Imagene's innovative development aligns with the notion that actionable (driver) genomic alterations will have a morphological effect on the tissue in a resolution that is impossible for the human eye to detect, but AI and deep learning models can. 

"We are honored to be recognized among these great Life Science and BioTech innovators as we continue to advance precision oncology in the fight against cancer," said Dean Bitan, co-founder and CEO at Imagene. "The cancer diagnosis process has evolved to include crucial genomic information; however, long turnaround time, tissue, and cost make its availability limited. Identifying gene alterations is key for improving patient care and guiding targeted therapeutic decisions; physicians should be able to make optimal treatment decisions in a timely and accurate manner. The availability of rapid molecular analysis can sometimes be the difference between life and death."

"Based on the NCCN guidelines, the identification of patient-specific actionable genomic alterations serves as the basis foundation of precision oncology and is utilized routinely for optimal and personalized treatment decisions that drive higher response and mortality rates. The need to use biological specimens and the extended time needed for the analysis and interpretation, as well as inadequate tissue biopsies result in patients not getting life-saving treatment quickly enough," said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. "Imagene's innovative solution opens the path to fast and accurate cancer diagnosis, demonstrating the huge advancement that AI-based genomic testing can offer to cancer patients' care. All our deep congratulations on winning 'Oncology Innovation of the Year!'" 

Imagene has developed 28 different models for actionable alterations across eight cancer types, including Lung, Colorectal, Bladder, Breast, Ovary, Hematology, Thyroid, and brain cancer. The detection accuracy level aligns with the current gold-standard methodologies showing an average sensitivity that is superior to the standard of care. Imagene real-time image-based biomarker detection takes about two minutes, it reduces cost and time significantly with high scalability and seamless integration with routine workflows.

About Imagene

Imagene is a precision oncology diagnosis company with the mission to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and clinical insights using only digitized biopsy images. Its multidisciplinary team is composed of a diverse group of experts from the fields of science, medicine, and deep learning. Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide, striving for fast and accurate cancer diagnosis, profiling patients for clinical trials, and accelerating the drug development process. For more information, visit

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services, and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information, visit

Contact Information:
Avital Rabani
Head of Marketing
[email protected]

Press Release Service by

Original Source: Imagene Named 'Oncology Innovation of the Year' at 2022 BioTech Breakthrough Awards